Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 6, 2003, Pages 1403-1407

  Griggs, Deborah J ^a   Marona, Herida ^a   Piddock, Laura J V ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Fluoroquinolone; Mutant selection; S. aureus

Indexed keywords

AMINO ACID; CIPROFLOXACIN; CYSTEINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GLUTAMIC ACID; GLYCINE; GREPAFLOXACIN; LEUCINE; LEVOFLOXACIN; LYSINE; MOXIFLOXACIN; NALIDIXIC ACID; OFLOXACIN; PHENYLALANINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; SPARFLOXACIN; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CODON; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STAPHYLOCOCCUS AUREUS;

AZA COMPOUNDS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLINES; STAPHYLOCOCCUS AUREUS;

EID: 0038647803     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg241     Document Type: Article

References (12)

1. Hooper, D. C. (2002). Fluoroquinolone resistance among Gram-positive cocci. Lancet Infectious Diseases 2, 530-8.
2. Ince, D., Zhang, X., Silver, L. C. & Hooper, D. C. (2002). Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrobial Agents and Chemotherapy 46, 3370-80.
3. Ng, E. Y., Trucksis, M. & Hooper, D. C. (1996). Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 40, 1881-8.
4. Fukuda, H. & Hiramatsu, K. (1999). Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 43, 410-2.
5. Takei, M., Fukuda, H., Kishii, R. & Hosaka, M. (2001). Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrobial Agents and Chemotherapy 45, 3544-7.
6. Griggs, D. J., Hall, M. C., Jin, Y. F. & Piddock, L. J. V. (1994). Quinolone resistance in veterinary isolates of Salmonella. Journal of Antimicrobial Chemotherapy 33, 1173-89.
7. Pitcher, D. G., Saunders, N. A. & Owen, R. J. (1989). Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Letters in Applied Microbiology 8, 151-6.
8. Sreedharan, S., Oram, M., Jensen, B., Peterson, L. R. & Fisher, L. M. (1990). DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. Journal of Bacteriology 172, 7260-2.
9. Wain, J., Hoa, N. T. T., Chinh, N. T., Vinh, H., Everett, M. J., Diep, T. S. et al. (1997). Quinolone resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clinical Infectious Diseases 25, 1404-10.
10. Kaatz, G. W. & Seo, S. M. (1997). Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 41, 2733-7.
11. Gootz, T. D., Zaniewski, R. P., Haskell, S. L., Kaczmarek, F. S. & Maurice, A. E. (1999). Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 43, 1845-55.
12. Ito, H., Yoshida, H., Bogaki-Shonnai, M., Niga, T., Hattori, H. & Nakamura, S. (1994). Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 38, 2014-23.